Pressroom
- March 14 Champions Oncology Reports Record Results for the Quarter Ended January 31, 2013
- March 8 Champions Oncology to Report Third Quarter Financial Results
- March 5 Champions Oncology Reports Changes to Board of Directors
- February 11 Champions Oncology Reports Successful Outcome from Technology Collaboration
- January 29 Champions Oncology Raises $9.3 Million in a Private Placement
- December 14 Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
- December 13 Champions Oncology Announces Geographic Expansion
- September 12 Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
- July 18 Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
- May 18 Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
- March 14 Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
- March 13 Champions Oncology will be exhibiting (Booth #1037) and presenting 5 posters at the 2012 AACR Annual Meeting
- December 14 Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
- November 2 Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
- September 13 Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
- July 15 Champions Oncology Reports Full Year 2011 Financial Results
- April 5 Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
- April 4 Champions Biotechnology Changes Name to Champions Oncology
- April 1 Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
- March 24 Champions Announces Technology Collaboration Utilizing Champions’ Tumorgraft™ Technology Platform for Oncology Drug Development
- March 7 Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
- January 14 Champions Biotechnology, Inc. announced today the resignation of Mark Schonau, Champions’ Chief Financial Officer
- December 7 Champions Biotechnology Announces Master Service Agreement with Teva Pharmaceutical Industries, Ltd. for the Evaluation of a Novel Oncology Compound
- October 28 Champions Biotechnology Reports Additions to its Management Team
- September 10 Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
- September 8 Champions Biotechnology Announces Agreement with Cephalon for the Evaluation of a Novel Oncology Compound using Predictive Biomerk Tumorgraft™ Platform
- April 20 Champions Biotechnology, Inc. and Morphotek®, Inc. Announce Agreement for an Oncology Evaluation Using Biomerk Tumorgraft™ Platform
- March 17 Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
- December 15 Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
- November 18 Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
- November 12 Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft™ Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
- October 27 Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
- October 26 Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts™
- October 13 U.S. Patent Issues for Champions Biotechnology’s Lead Oncology Drug
- September 14 Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
- September 10 Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
- September 9 Champions Biotechnology to Present at Rodman & Renshaw’s Eleventh Annual Healthcare Conference
- September 1 Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
- August 27 Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
- July 16 Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft™ Testing
- June 1 Champions Biotechnology, Inc. Launches Personalized Cancer Treatment.com
- April 8 Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand its Personalized Oncology Business
- March 18 Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
- February 3 Champions Biotechnology Partners with Gradalis Inc. and Mary Crowley Cancer Research Center to Develop Personalized Vaccines for Cancer Patients
- January 20 Champions Biotechnology, Inc. Appoints Three Key Executives to Management Team
- January 12 Champions Biotechnology and Concordia Pharmaceuticals Establish Royalty Agreement for Novel Oncology Drug
- December 18 Champions Biotechnology Partners to Establish Agreements for Preclinical Evaluation of Oncology Drugs
- December 18 Champions Biotechnology Reports Fiscal 2009 Second Quarter Financial Results
- November 13 Of Mice and Men: Award-Winning Oncologist Leads New Advancement in Personalized Medicine
- September 16 Champions Biotechnology Reports Fiscal 2009 First Quarter Financial Results
- August 14 Champions Biotechnology, Inc. Retains The Investor Relations Group
- July 30 Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
- July 17 Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
- May 7 Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
- May 6 Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
- April 23 Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
- April 1 Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
- March 6 Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008.
- October 23 Dr. David Sidransky appointed Chairman of Champions Biotechnology, Inc.
- August 14 Dr. David Sidransky Appointed Director of Champions Biotechnology, Inc.
- June 11 Dr. Manuel Hidalgo Appointed Director and Scientific Advisor of Champions Biotechnology, Inc.
- May 21 Champions Biotechnology, Inc. acquires Biomerk, Inc.
- February 14 Champions Biotechnology, Inc. acquires rights to cancer drug candidates
- January 22 Champions Sports, Inc. changes name to Champions Biotechnology, Inc.